Risdiplam utilization, adherence, and associated health care costs for patients with spinal muscular atrophy: a United States retrospective claims database analysis

Abstract Background Spinal muscular atrophy (SMA) is a genetic neuromuscular disease associated with progressive loss of motor function. Risdiplam, a daily oral therapy, was approved in the United States for the treatment of SMA. Risdiplam’s effectiveness depends on patient adherence to the treatmen...

Full description

Saved in:
Bibliographic Details
Main Authors: Anish Patel, Walter Toro, Min Yang, Wei Song, Raj Desai, Mingchen Ye, Nadia Tabatabaeepour, Omar Dabbous
Format: Article
Language:English
Published: BMC 2024-12-01
Series:Orphanet Journal of Rare Diseases
Subjects:
Online Access:https://doi.org/10.1186/s13023-024-03399-0
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841559131476983808
author Anish Patel
Walter Toro
Min Yang
Wei Song
Raj Desai
Mingchen Ye
Nadia Tabatabaeepour
Omar Dabbous
author_facet Anish Patel
Walter Toro
Min Yang
Wei Song
Raj Desai
Mingchen Ye
Nadia Tabatabaeepour
Omar Dabbous
author_sort Anish Patel
collection DOAJ
description Abstract Background Spinal muscular atrophy (SMA) is a genetic neuromuscular disease associated with progressive loss of motor function. Risdiplam, a daily oral therapy, was approved in the United States for the treatment of SMA. Risdiplam’s effectiveness depends on patient adherence to the treatment regimen. This retrospective claims database analysis assessed real-world treatment adherence and persistence, and all-cause health care costs by adherence status, for patients with SMA receiving risdiplam. Outcomes were summarized by SMA types (1−4) and age groups (0–2, 3–5, 6–17, and ≥ 18 years). Results 86 patients with ≥ 1 SMA diagnosis, risdiplam treatment, and ≥ 6 months of continuous enrollment after the index date (SMA diagnosis) were identified in the IQVIA PharMetrics® Plus database (01/01/2020−06/30/2022). One patient had SMA type 1 (a 1-year-old boy), 18 had type 2 (mean ± SD age: 7.9 ± 5.7 years; 61% female), 47 had type 3 (17.3 ± 10.2 years; 55% female), and 20 had type 4 (38.2 ± 11.6 years; 55% female). The mean proportion of days covered (PDC) with risdiplam was 0.89 overall, ranging from 0.88 for SMA type 4 to 0.97 for type 1. The majority (83.7%) of patients were adherent to risdiplam (PDC ≥0.80), ranging from 75.0% for type 4 to 100% for type 1. Adherence ranged from 76.5% among 6–12-year-olds to 100% among 0–2-year-olds. Compared with adherent patients, nonadherent patients had higher median total health care costs by $335,049 for type 2, $41,204 for type 3, and $12,223 for type 4. Among adherent patients, patients with PDC between 0.90 and 1.00 had lower costs compared with patients with PDC between 0.80 and 0.90. Conclusions Nonadherence to risdiplam was observed in the first year of treatment, especially for patients with SMA type 4 and patients aged 6–12 years. Nonadherence was associated with higher all-cause health care costs, with the most pronounced cost difference for SMA type 2. For adherent patients, those who were highly adherent incurred lower health care costs. These findings underscore the importance of treatment adherence and persistence for patients with SMA receiving risdiplam, particularly for younger children and those with greater disease severity.
format Article
id doaj-art-419efc6b945542dc8a1496b8f3623268
institution Kabale University
issn 1750-1172
language English
publishDate 2024-12-01
publisher BMC
record_format Article
series Orphanet Journal of Rare Diseases
spelling doaj-art-419efc6b945542dc8a1496b8f36232682025-01-05T12:45:57ZengBMCOrphanet Journal of Rare Diseases1750-11722024-12-0119111110.1186/s13023-024-03399-0Risdiplam utilization, adherence, and associated health care costs for patients with spinal muscular atrophy: a United States retrospective claims database analysisAnish Patel0Walter Toro1Min Yang2Wei Song3Raj Desai4Mingchen Ye5Nadia Tabatabaeepour6Omar Dabbous7Novartis Gene Therapies, Inc.Novartis Gene Therapies, Inc.Analysis Group, Inc.Analysis Group, Inc.Analysis Group, Inc.Analysis Group, Inc.Analysis Group, Inc.Novartis Gene Therapies, Inc.Abstract Background Spinal muscular atrophy (SMA) is a genetic neuromuscular disease associated with progressive loss of motor function. Risdiplam, a daily oral therapy, was approved in the United States for the treatment of SMA. Risdiplam’s effectiveness depends on patient adherence to the treatment regimen. This retrospective claims database analysis assessed real-world treatment adherence and persistence, and all-cause health care costs by adherence status, for patients with SMA receiving risdiplam. Outcomes were summarized by SMA types (1−4) and age groups (0–2, 3–5, 6–17, and ≥ 18 years). Results 86 patients with ≥ 1 SMA diagnosis, risdiplam treatment, and ≥ 6 months of continuous enrollment after the index date (SMA diagnosis) were identified in the IQVIA PharMetrics® Plus database (01/01/2020−06/30/2022). One patient had SMA type 1 (a 1-year-old boy), 18 had type 2 (mean ± SD age: 7.9 ± 5.7 years; 61% female), 47 had type 3 (17.3 ± 10.2 years; 55% female), and 20 had type 4 (38.2 ± 11.6 years; 55% female). The mean proportion of days covered (PDC) with risdiplam was 0.89 overall, ranging from 0.88 for SMA type 4 to 0.97 for type 1. The majority (83.7%) of patients were adherent to risdiplam (PDC ≥0.80), ranging from 75.0% for type 4 to 100% for type 1. Adherence ranged from 76.5% among 6–12-year-olds to 100% among 0–2-year-olds. Compared with adherent patients, nonadherent patients had higher median total health care costs by $335,049 for type 2, $41,204 for type 3, and $12,223 for type 4. Among adherent patients, patients with PDC between 0.90 and 1.00 had lower costs compared with patients with PDC between 0.80 and 0.90. Conclusions Nonadherence to risdiplam was observed in the first year of treatment, especially for patients with SMA type 4 and patients aged 6–12 years. Nonadherence was associated with higher all-cause health care costs, with the most pronounced cost difference for SMA type 2. For adherent patients, those who were highly adherent incurred lower health care costs. These findings underscore the importance of treatment adherence and persistence for patients with SMA receiving risdiplam, particularly for younger children and those with greater disease severity.https://doi.org/10.1186/s13023-024-03399-0AdherencePersistenceClaims database analysisHealth care costsHealth care utilizationRisdiplam
spellingShingle Anish Patel
Walter Toro
Min Yang
Wei Song
Raj Desai
Mingchen Ye
Nadia Tabatabaeepour
Omar Dabbous
Risdiplam utilization, adherence, and associated health care costs for patients with spinal muscular atrophy: a United States retrospective claims database analysis
Orphanet Journal of Rare Diseases
Adherence
Persistence
Claims database analysis
Health care costs
Health care utilization
Risdiplam
title Risdiplam utilization, adherence, and associated health care costs for patients with spinal muscular atrophy: a United States retrospective claims database analysis
title_full Risdiplam utilization, adherence, and associated health care costs for patients with spinal muscular atrophy: a United States retrospective claims database analysis
title_fullStr Risdiplam utilization, adherence, and associated health care costs for patients with spinal muscular atrophy: a United States retrospective claims database analysis
title_full_unstemmed Risdiplam utilization, adherence, and associated health care costs for patients with spinal muscular atrophy: a United States retrospective claims database analysis
title_short Risdiplam utilization, adherence, and associated health care costs for patients with spinal muscular atrophy: a United States retrospective claims database analysis
title_sort risdiplam utilization adherence and associated health care costs for patients with spinal muscular atrophy a united states retrospective claims database analysis
topic Adherence
Persistence
Claims database analysis
Health care costs
Health care utilization
Risdiplam
url https://doi.org/10.1186/s13023-024-03399-0
work_keys_str_mv AT anishpatel risdiplamutilizationadherenceandassociatedhealthcarecostsforpatientswithspinalmuscularatrophyaunitedstatesretrospectiveclaimsdatabaseanalysis
AT waltertoro risdiplamutilizationadherenceandassociatedhealthcarecostsforpatientswithspinalmuscularatrophyaunitedstatesretrospectiveclaimsdatabaseanalysis
AT minyang risdiplamutilizationadherenceandassociatedhealthcarecostsforpatientswithspinalmuscularatrophyaunitedstatesretrospectiveclaimsdatabaseanalysis
AT weisong risdiplamutilizationadherenceandassociatedhealthcarecostsforpatientswithspinalmuscularatrophyaunitedstatesretrospectiveclaimsdatabaseanalysis
AT rajdesai risdiplamutilizationadherenceandassociatedhealthcarecostsforpatientswithspinalmuscularatrophyaunitedstatesretrospectiveclaimsdatabaseanalysis
AT mingchenye risdiplamutilizationadherenceandassociatedhealthcarecostsforpatientswithspinalmuscularatrophyaunitedstatesretrospectiveclaimsdatabaseanalysis
AT nadiatabatabaeepour risdiplamutilizationadherenceandassociatedhealthcarecostsforpatientswithspinalmuscularatrophyaunitedstatesretrospectiveclaimsdatabaseanalysis
AT omardabbous risdiplamutilizationadherenceandassociatedhealthcarecostsforpatientswithspinalmuscularatrophyaunitedstatesretrospectiveclaimsdatabaseanalysis